RB Global Free cash flow decreased by 7.5% to $172.60M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 68.4%, from $102.50M to $172.60M. Over 4 years (FY 2021 to FY 2025), Free cash flow shows an upward trend with a 23.6% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase suggests improved operational efficiency or reduced capital intensity, providing more flexibility for capital allocation. A decrease may indicate higher investment in R&D or infrastructure, or potential challenges in converting earnings into cash.
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and m...
Large-cap medical device and pharmaceutical peers typically maintain strong, positive free cash flow, though levels vary based on the intensity of R&D spending and the lifecycle stage of major product lines.
free_cash_flow| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $27.64M | $90.36M | $10.67M | $183.10M | $10.40M | $44.10M | $193.50M | -$80.80M | $38.50M | $95.40M | $263.00M | $79.60M | $308.60M | $248.50M | $127.90M | $102.50M | $241.70M | $188.50M | $186.50M | $172.60M |
| QoQ Change | — | +226.9% | -88.2% | >999% | -94.3% | +324.0% | +338.8% | -141.8% | +147.6% | +147.8% | +175.7% | -69.7% | +287.7% | -19.5% | -48.5% | -19.9% | +135.8% | -22.0% | -1.1% | -7.5% |
| YoY Change | — | — | — | — | -62.4% | -51.2% | >999% | -144.1% | +270.2% | +116.3% | +35.9% | +198.5% | +701.6% | +160.5% | -51.4% | +28.8% | -21.7% | -24.1% | +45.8% | +68.4% |